Location Sydney, New South Wales, Australia Regions Asia-Pacific (APAC), Australasia Gender Male
Facebook View on Facebook LinkedIn View on LinkedIn
Andrew Sneddon is the Chairman of the Board of Directors at Elastagen Pty Ltd. since September 2008.
Andrew is a former Partner of PricewaterhouseCoopers (PWC). In his PWC role, Andrew led the technology practise for a period of time and specialised in fast growth and emerging technology companies working with many companies from start-ups to
successful global corporations.
In more recent years Andrew was the Partner leading the firm’s Australian Life Sciences Practice. Andrew has extensive experience in a wide range of technical areas including mergers and acquisitions, business and strategic planning, audit, valuation, capital raising and stock exchange listings on the Australian, NASDAQ and London Stock Exchanges.
Andrew has worked across a broad range of industries and is currently a Non-Executive Director of Innate Immunotherapeutics Limited, ClearView Wealth Limited and the Chairman of ServiceRocket Inc, Fusion Payments Limited and TGR BioSciences Pty Ltd.
Andrew is also a Member of the Audit and Compliance Committees of the Crescent Capital Private Equity Funds.
Andrew earned his Bachelor's degree in Economics from Macquarie University in 1985.
